5 research outputs found
Evaluation of SARS-CoV-2-Specific TâCell Activation with a Rapid On-Chip IGRA
Interferon-gamma release assays (IGRAs) that measure
pathogen-specific
T-cell response rates can provide a more reliable estimate of protection
than specific antibody levels but have limited potential for widespread
use due to their workflow, personnel, and instrumentation demands.
The major vaccines for SARS-CoV-2 have demonstrated substantial efficacy
against all of its current variants, but approaches are needed to
determine how these vaccines will perform against future variants,
as they arise, to inform vaccine and public health policies. Here
we describe a rapid, sensitive, nanolayer polylysine-integrated microfluidic
chip IGRA read by a fluorescent microscope that has a 5 h sample-to-answer
time and uses âŒ25 ÎŒL of a fingerstick whole blood sample.
Results from this assay correlated with those of a comparable clinical
IGRA when used to evaluate the T-cell response to SARS-CoV-2 peptides
in a population of vaccinated and/or infected individuals. Notably,
this streamlined and inexpensive assay is suitable for high-throughput
analyses in resource-limited settings for other infectious diseases